Citius Oncology (CTOR) investor relations material

Company overview and business model

• Focuses on developing and commercializing targeted oncology therapies, leveraging new formulations of approved drugs and expanded indications for existing therapies.

• Lead product, LYMPHIR, is an engineered IL-2 diphtheria toxin fusion protein for persistent or recurrent CTCL, approved by the FDA in August 2024 and launched in December 2025.

• Commercialization strategy includes direct U.S. sales and international partnerships, with a targeted oncology sales force focused on major cancer centers.

• Became a standalone public company via a reverse merger in August 2024, with Citius Pharmaceuticals as the majority owner.

Financial performance and metrics

• Raised approximately $11.5 million in gross proceeds from a May 2026 warrant inducement transaction.

• Secured a loan facility of up to $25 million, with $10 million funded in May 2026 and additional tranches contingent on revenue and liquidity milestones.

• Loans bear interest at a minimum of 12.75% and mature in November 2029.

• May receive up to $26.5 million in gross proceeds if all warrants are exercised for cash.

Use of proceeds and capital allocation

• Proceeds from warrant exercises, if any, are allocated to working capital; no specific allocation to projects or initiatives.

• All proceeds from the resale of shares by selling stockholders go to those stockholders, not the company.